ABUS Stock: Earnings, Dividends & Analyst Estimates

Company Overview:

Market Cap: $943.91M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $3.50 - $5.45

10 Year ABUS Performance Metrics:

Total Return (with DRIP): 37.4% (3.22% CAGR)

Total Return (no DRIP): 37.4% (3.22% CAGR)

Share Price: 39.0% (3.34% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $13,736

Total Return $ (with DRIP): $3,736

ABUS Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

ABUS Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for ABUS

Based on past 10-year performance, here are ABUS growth metrics:

Share price CAGR of +3.34%
Dividend CAGR of +0%

Using ABUS CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	ABUS (DRIP)	ABUS - No DRIP
Current Price	$4.78	$4.78
Start Shares	2,092.05	2,092.05
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	2,092.05	2,092.05
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$4.78	$4.78
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - ABUS

NOTE: Above numbers are our estimate based on ABUS's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Arbutus Biopharma Corporation (ABUS) had its IPO on , and is traded on NASDAQ stock exchange.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response. The company’s work centers on advancing virology-based therapies that may contribute to improved treatment options for patients living with chronic hepatitis B. Arbutus Biopharma Corporation operates within the broader biotechnology sector, where its current programs, proprietary drug candidates, and infectious-disease focus position it as a specialized developer of novel therapeutics.

ABUS website: https://www.arbutusbio.com